Consumer attitudes about opioid addiction treatment: A focus group study in New York City

Journal of Opioid Management

Volumn 9, Issue 2, 2013, Pages 111-119

  Sohler, Nancy L ^a   Weiss, Linda ^b   Egan, James E ^c   López, Carolina M ^d   Favaro, Jamie ^e   Cordero, Robert ^f   Cunningham, Chinazo O ^g  

^a CITY COLLEGE OF NEW YORK   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d New York Harm Reduction Educators   (United States)

^e Washington Heights CORNER Project   (United States)

^f CitiWide Harm Reduction Inc   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Buprenorphine; Heroin dependence; Methadone; Qualitative research

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; AUDIO RECORDING; CLINICAL ARTICLE; CONSUMER ATTITUDE; FEMALE; HUMAN; MALE; OPIATE ADDICTION; QUALITATIVE ANALYSIS; UNITED STATES;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DRUG USERS; FEMALE; FOCUS GROUPS; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; METHADONE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; NEW YORK CITY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT SATISFACTION; QUALITATIVE RESEARCH;

EID: 84877867204     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2013.0152     Document Type: Article

References (38)

1. Substance Abuse and Mental Health Services Administration: Results from the 2007 National Survey on Drug Use and Health: National Findings, 2008.
2. Substance Abuse and Mental Health Services Administration: Drug Abuse Warning Network, 2009: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 11-4659, DAWN Series D-35. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
3. Cicero TJ, Inciardi JA, Munoz A: Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005; 6(10): 662-672. (Pubitemid 41395058)
4. Sung HE, Richter L, Vaughan R, et al.: Nonmedical use of prescription opioids among teenagers in the United States: Trends and correlates. J Adolesc Health. 2005; 37(1): 44-51. (Pubitemid 40826518)
5. Stancliff S, Myers JE, Steiner S, et al.: Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002; 79(4): 571-578. (Pubitemid 36076530)
6. Fiellin DA: The first three years of buprenorphine in the United States: Experience to date and future directions. J Addict Med. 2007; 1(2): 62-67.
7. Cunningham CO, Kunins HV, Roose RJ, et al.: Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007; 22(9): 1325-1329. (Pubitemid 47247300)
8. Kissin W, McLeod C, Sonnefeld J, et al.: Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006; 25(4): 91-103. (Pubitemid 44707293)
9. Cicero TJ, Inciardi JA: Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med. 2005; 353(17): 1863-1865. (Pubitemid 41549906)
10. Cicero TJ, Surratt HL, Inciardi J: Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007; 3(6): 302-308. (Pubitemid 351166541)
11. Smith MY, Bailey JE, Woody GE, et al.: Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis. 2007; 26(3): 107-111. (Pubitemid 47367833)
12. Kresina TF, Litwin AH, Marion I, et al.: Federal government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. J Drug Policy Anal. 2009; 2: 1-23.
13. Cunningham C, Giovanniello A, Sacajiu G, et al.: Buprenorphine treatment in an urban community health center: What to expect. Fam Med. 2008; 40(7): 500-506.
14. Lee JD, Grossman E, DiRocco D, et al.: Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009; 24(2): 226-232.
15. Magura S, Lee SJ, Salsitz EA, et al.: Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007; 26(2): 13-23. (Pubitemid 47413818)
16. Sohler NL, Li X, Kunins HV, et al.: Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2010; 38(2): 153-159.
17. Egan JE, Netherland J, Gass J, et al.: Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. J Acquir Immune Defic Syndr. 2011; 56(S1): S46-S53.
18. Weiss L, Netherland J, Egan JE, et al.: Integration of buprenorphine/naloxone treatment into HIV clinical care: Lessons from the BHIVES Collaborative. J Acquir Immune Defic Syndr. 2011; 56(S1): S68-S75.
19. Schwartz RP, Kelly SM, O'Grady KE, et al.: Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008; 17(5): 396-401.
20. Korthuis PT, Gregg J, Rogers WE, et al.: Patients' reasons for choosing office-based buprenorphine: Preference for patient-centered care. J Addict Med. 2010; 4(4): 204-210.
21. Parchman ML, Burge SK: The patient-physician relationship, primary care attributes, and preventive services. Fam Med. 2003; 36(1): 22-27.
22. Schneider J, Kaplan SH, Greenfield S, et al.: Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004; 19(11): 1096-1103. (Pubitemid 39552579)
23. Meredith LS, Orlando M, Humphrey N, et al.: Are better ratings of the patient-provider relationship associated with higher quality care for depression? Med Care. 2001; 39(4): 349-360. (Pubitemid 33603634)
24. Spire B, Lucas GM, Carried MP: Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007; 18(4): 262-270. (Pubitemid 47126278)
25. Wish ED, Artigiani E, Billing A, et al.: The emerging buprenorphine epidemic in the United States. J Addict Dis. 2012; 31(1): 3-7.
26. Altice FL, Springer S, Buitrago M, et al.: Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003; 80(3): 416-427. (Pubitemid 37486645)
27. Cunningham CO, Sanchez JP, Heller DI, et al.: Assessment of a medical outreach program to improve access to HIV care among marginalized individuals. Am J Public Health. 2007; 97(10): 1758-1761. (Pubitemid 351182282)
28. Macalino GE, Hogan JW, Mitty JA, et al.: A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007; 21(11): 1473-1477. (Pubitemid 46988008)
29. McNeely J, Drucker E, Hartel D, et al.: Office-based methadone prescribing: Acceptance by inner-city practitioners in New York. J Urban Health. 2000; 77(1): 96-102. (Pubitemid 30127209)
30. Sheridan J, Strang J, Barber N, et al.: Role of community pharmacies in relation to HIV prevention and drug misuse: Findings from the 1995 national survey in England and Wales. BMJ. 1996; 313(7052): 272-274. (Pubitemid 26254739)
31. Weiss L, Egan J, Botsko M, et al.: The BHIVES collaborative: Organization and evaluation of a multisite demonstration of integrated buprenorphine/ naloxone and HIV treatment. J Acquir Immune Defic Syndr. 2011; 56: S7-S13.
32. Sullivan LE, Bruce RD, Haltiwanger D, et al.: Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis. 2006; 43(supplement 4): S191-S196. (Pubitemid 44901887)
33. Yokell MA, Zaller ND, Green TC, et al.: Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev. 2011; 4(1): 28-41.
34. Monte AA, Mandell T, Wilford BB, et al.: Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009; 28(3): 226-231.
35. Gwin MS, Kelly SM, Brown BS, et al.: Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009; 18(5): 346-355.
36. Johanson CE, Arfken CL, di Menza S, et al.: Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012; 120: 1-3.
37. Bazazi AR, Yokell M, Fu JJ, et al.: Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011; 5(3): 175-180.
38. Schuman-Olivier Z, Albanese M, Nelson SE, et al.: Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010; 39(1): 41-50.